Page last updated: 2024-10-16

gamma-aminobutyric acid and Chemical Dependence

gamma-aminobutyric acid has been researched along with Chemical Dependence in 167 studies

gamma-Aminobutyric Acid: The most common inhibitory neurotransmitter in the central nervous system.
gamma-aminobutyric acid : A gamma-amino acid that is butanoic acid with the amino substituent located at C-4.

Research Excerpts

ExcerptRelevanceReference
" Gabapentin is a relatively new anticonvulsant being investigated for potential use in the treatment of bipolar disorder (BD), anxiety disorders, behavioral dyscontrol, and substance use disorders."8.80Gabapentin: a review of published experience in the treatment of bipolar disorder and other psychiatric conditions. ( Letterman, L; Markowitz, JS, 1999)
"Gabapentin (Neurontin) is approved by the US Food and Drug Administration for treatment of epilepsy and post-herpetic neuralgia."7.75Gabapentin-induced delirium and dependence. ( Kahn, DA; Kruszewski, SP; Paczynski, RP, 2009)
"Gabapentin is a relatively new anticonvulsant being investigated for potential use in the treatment of bipolar disorder (BD), anxiety disorders, behavioral dyscontrol, and substance use disorders."6.40Gabapentin: a review of published experience in the treatment of bipolar disorder and other psychiatric conditions. ( Letterman, L; Markowitz, JS, 1999)
"Alprazolam is an anxiolytic compound that can lead to psychological and physiological dependence especially with prolonged use."5.91Physiologically based pharmacokinetic and pharmacodynamic modelling of alprazolam: Implications for anxiety and addiction. ( Burkat, PM, 2023)
" This study utilized physiologically based pharmacokinetic (PK) and pharmacodynamic (PD) modelling to further examine the underlying mechanisms of anxiety treatment and addiction."5.91Physiologically based pharmacokinetic and pharmacodynamic modelling of alprazolam: Implications for anxiety and addiction. ( Burkat, PM, 2023)
" With repetitive administrations, peak concentration is 59 nM for a 2-mg alprazolam immediate-release dose and 122 nM for a 10-mg extended-release dose."5.91Physiologically based pharmacokinetic and pharmacodynamic modelling of alprazolam: Implications for anxiety and addiction. ( Burkat, PM, 2023)
"Both schizophrenia (SZ) and substance abuse (SA) exhibit significant heritability."5.51N-Methyl-d-aspartate receptor co-agonist availability affects behavioral and neurochemical responses to cocaine: insights into comorbid schizophrenia and substance abuse. ( Bergman, J; Carlezon, WA; Coyle, JT; Desai, RI; Donahue, RJ; Doyle, MR; Landino, SM; Presti, KT; Puhl, MD; Takagi, S, 2019)
"Gabapentin is a central nervous system inhibitory agent with likely gamma-aminobutyric acid (GABA)-ergic and non-GABAergic mechanisms of action."5.35Gabapentin-induced delirium and dependence. ( Kahn, DA; Kruszewski, SP; Paczynski, RP, 2009)
"Epilepsy is a common condition in people with learning disabilities with many patients continuing to suffer from seizures despite antiepileptic drug (AED) treatment."5.30A naturalistic study of the use of vigabatrin, lamotrigine and gabapentin in adults with learning disabilities. ( Bhaumik, S; Branford, D; Duggirala, C; Ismail, IA, 1997)
"Lamotrigine caused increased seizures in 24% of patients, especially when prescribed at a higher dose."5.30A naturalistic study of the use of vigabatrin, lamotrigine and gabapentin in adults with learning disabilities. ( Bhaumik, S; Branford, D; Duggirala, C; Ismail, IA, 1997)
"gov, and US FDA data, indexed through 28 July 2016, utilizing the following searches: pregabalin OR gabapentin OR gabapentinoid AND one of the following: abuse, misuse, overdose, or substance-related disorders[MESH], was conducted."4.95Abuse and Misuse of Pregabalin and Gabapentin. ( Evoy, KE; Morrison, MD; Saklad, SR, 2017)
" Gabapentin is a relatively new anticonvulsant being investigated for potential use in the treatment of bipolar disorder (BD), anxiety disorders, behavioral dyscontrol, and substance use disorders."4.80Gabapentin: a review of published experience in the treatment of bipolar disorder and other psychiatric conditions. ( Letterman, L; Markowitz, JS, 1999)
"Pregabalin, primarily used to manage neuropathic pain and fibromyalgia, is categorized as a Schedule V drug (ie, lowest potential for abuse) in the US Drug Enforcement Administration's Controlled Substances Act."3.76Potential for pregabalin abuse or diversion after past drug-seeking behavior. ( Coren, JS; Filipetto, FA; Zipp, CP, 2010)
"Gabapentin (Neurontin) is approved by the US Food and Drug Administration for treatment of epilepsy and post-herpetic neuralgia."3.75Gabapentin-induced delirium and dependence. ( Kahn, DA; Kruszewski, SP; Paczynski, RP, 2009)
" One promising pharmacological agent in BDZ discontinuation might be the newer anti-epileptic pregabalin, already successfully tested in the treatment of anxiety disorders."3.74Pregabalin in the discontinuation of long-term benzodiazepines' use. ( Karakatsanis, NA; Karapoulios, E; Konstantakopoulos, G; Kontoangelos, KA; Kouzoupis, AV; Masdrakis, VG; Oulis, P; Papadimitriou, GN, 2008)
"Histamine is a biogenic amine with four types of receptors."2.82Therapeutic Potential of Histamine H3 Receptors in Substance Use Disorders. ( Di Ciano, P; Hendershot, CS; Le Foll, B, 2022)
"Substance use disorders are a leading cause of morbidity and mortality, and available pharmacological treatments are of modest efficacy."2.82Therapeutic Potential of Histamine H3 Receptors in Substance Use Disorders. ( Di Ciano, P; Hendershot, CS; Le Foll, B, 2022)
" The starting dosage of pregabalin was 75 mg/day and was increased up to as much as 300 mg/day, depending on the individual patient's condition, while tapering off hypnotics."2.79Effects of pregabalin in patients with hypnotic-dependent insomnia. ( Cho, YW; Song, ML, 2014)
" Using a double-blind, randomized, crossover design, 16 healthy volunteers were administered (in separate sessions) capsules containing placebo, 75 mg pregabalin, 150 mg pregabalin, 10 mg oxycodone, and 75 mg pregabalin combined with 10 mg oxycodone."2.77Subjective, psychomotor, and physiological effects of pregabalin alone and in combination with oxycodone in healthy volunteers. ( Coalson, DW; Paice, JA; Zacny, JP, 2012)
"Gabapentin (1200 mg/day) was additionally added in group B."2.71Gabapentin in the management of pentazocine dependence: a potent analgesic--anticraving agent. ( Jain, MK; Kumar, P, 2003)
"Gabapentin is an important adjuvant to the management of opiate dependence both in acute detoxification as well as stabilisation phase."2.71Gabapentin in the management of pentazocine dependence: a potent analgesic--anticraving agent. ( Jain, MK; Kumar, P, 2003)
"Risk factors include a history of substance abuse, particularly opioids, and psychiatric co-morbidities."2.55Abuse and Misuse of Pregabalin and Gabapentin. ( Evoy, KE; Morrison, MD; Saklad, SR, 2017)
"Gabapentin was misused primarily for recreational purposes, self-medication or intentional self-harm and was misused alone or in combination with other substances, especially opioids, benzodiazepines and/or alcohol."2.53Gabapentin misuse, abuse and diversion: a systematic review. ( Havens, JR; Smith, RV; Walsh, SL, 2016)
"Databases were searched for peer-reviewed papers demonstrating gabapentin misuse, characterized by taking a larger dosage than prescribed or taking gabapentin without a prescription, and diversion."2.53Gabapentin misuse, abuse and diversion: a systematic review. ( Havens, JR; Smith, RV; Walsh, SL, 2016)
"Individuals with histories of drug abuse were most often involved in its misuse."2.53Gabapentin misuse, abuse and diversion: a systematic review. ( Havens, JR; Smith, RV; Walsh, SL, 2016)
"Drug addiction is characterized by widespread abnormalities in brain function and neurochemistry, including drug-associated effects on concentrations of the excitatory and inhibitory neurotransmitters glutamate and gamma-aminobutyric acid (GABA), respectively."2.53Neuroimaging markers of glutamatergic and GABAergic systems in drug addiction: Relationships to resting-state functional connectivity. ( London, ED; Moeller, SJ; Northoff, G, 2016)
"A history of alcohol or substance abuse appears to be an important part of a patient's medical history when evaluating their risk for addiction and dependence behaviors."2.53Gabapentin: Abuse, Dependence, and Withdrawal. ( Mersfelder, TL; Nichols, WH, 2016)
" Overall, pregabalin is characterized by higher potency, quicker absorption rates and greater bioavailability levels than gabapentin."2.50Misuse and abuse of pregabalin and gabapentin: cause for concern? ( Schifano, F, 2014)
"Problematic compounds may cause seizures either acutely or on withdrawal: Their use may reduce effectiveness of antiepileptic drugs, or may simply promote and enhance chaotic lifestyles."2.48Alcohol and drugs in epilepsy: pathophysiology, presentation, possibilities, and prevention. ( Borland, W; Leach, JP; Mohanraj, R, 2012)
" In both conditions, PGB was found efficacious with significant improvement in withdrawal symptoms at the dosage ranges of 150-450 mg/day (AD) and 225-900 mg/day (BD)."2.46Pregabalin in the treatment of alcohol and benzodiazepines dependence. ( Konstantakopoulos, G; Oulis, P, 2010)
"Chronic pain is now viewed as a biopsychosocial phenomenon, in which biological, psychological, and social factors are at work."2.44Practical management strategies for the chronic pain patient. ( Forde, G; Stanos, S, 2007)
"Drug addiction is a process beginning with the initial exposure to a drug of abuse, and leading, in some individuals, to chronic habitual use, and high rates of relapse."2.44Microdialysis and the neurochemistry of addiction. ( Kalivas, PW; Torregrossa, MM, 2008)
"The successful intervention into alcohol dependence and craving brought about by baclofen in both human and animal studies elucidates glutamatergic mechanisms in alcoholism whereas the role of the dopamine transporter, in conjunction with both the noradrenergic and serotonergic transporters, are implicated in cocaine dependence and craving."2.42Gene-environment interplay in alcoholism and other substance abuse disorders: expressions of heritability and factors influencing vulnerability. ( Archer, T; Beninger, RJ; Kostrzewa, RM; Palomo, T, 2004)
"Conventional wisdom, and even well-reasoned theoretical mechanisms, suggests that the chronic use of psychoactive substances would impair cognitive functioning of individuals."2.42Cognitive impairment in substance abuse. ( Cellucci, T; Hedt, J; Jarchow, A; Vik, PW, 2004)
"Gabapentin is a relatively new anticonvulsant being investigated for potential use in the treatment of bipolar disorder (BD), anxiety disorders, behavioral dyscontrol, and substance use disorders."2.40Gabapentin: a review of published experience in the treatment of bipolar disorder and other psychiatric conditions. ( Letterman, L; Markowitz, JS, 1999)
"Phencyclidine (PCP) is a major drug of abuse as well as a 'drug of choice' among substance abusers in the U."2.37[Phencyclidine, a drug which induces psychosis: its neuropharmacological actions]. ( Furukawa, H; Kameyama, T; Nabeshima, T, 1984)
" This study utilized physiologically based pharmacokinetic (PK) and pharmacodynamic (PD) modelling to further examine the underlying mechanisms of anxiety treatment and addiction."1.91Physiologically based pharmacokinetic and pharmacodynamic modelling of alprazolam: Implications for anxiety and addiction. ( Burkat, PM, 2023)
" With repetitive administrations, peak concentration is 59 nM for a 2-mg alprazolam immediate-release dose and 122 nM for a 10-mg extended-release dose."1.91Physiologically based pharmacokinetic and pharmacodynamic modelling of alprazolam: Implications for anxiety and addiction. ( Burkat, PM, 2023)
"Alprazolam is an anxiolytic compound that can lead to psychological and physiological dependence especially with prolonged use."1.91Physiologically based pharmacokinetic and pharmacodynamic modelling of alprazolam: Implications for anxiety and addiction. ( Burkat, PM, 2023)
"Flunitrazepam has greater potency and higher affinity for the type A GABA receptor than most benzodiazepines."1.62Sedative-Hypnotic Agents That Impact Gamma-Aminobutyric Acid Receptors: Focus on Flunitrazepam, Gamma-Hydroxybutyric Acid, Phenibut, and Selank. ( Doyno, CR; White, CM, 2021)
" Chronic use of these GABAergic drugs can lead to significant withdrawal syndromes."1.62Sedative-Hypnotic Agents That Impact Gamma-Aminobutyric Acid Receptors: Focus on Flunitrazepam, Gamma-Hydroxybutyric Acid, Phenibut, and Selank. ( Doyno, CR; White, CM, 2021)
"Flunitrazepam is a newer benzodiazepine that is preferentially used recreationally and to facilitate sexual assault."1.62Sedative-Hypnotic Agents That Impact Gamma-Aminobutyric Acid Receptors: Focus on Flunitrazepam, Gamma-Hydroxybutyric Acid, Phenibut, and Selank. ( Doyno, CR; White, CM, 2021)
"Both schizophrenia (SZ) and substance abuse (SA) exhibit significant heritability."1.51N-Methyl-d-aspartate receptor co-agonist availability affects behavioral and neurochemical responses to cocaine: insights into comorbid schizophrenia and substance abuse. ( Bergman, J; Carlezon, WA; Coyle, JT; Desai, RI; Donahue, RJ; Doyle, MR; Landino, SM; Presti, KT; Puhl, MD; Takagi, S, 2019)
"Gabapentin misuse has been associated with drug-related harm and increased healthcare service utilization in a few studies, including a recent large-sample analysis of commercially insured enrollees in the United States (U."1.48Policies to mitigate nonmedical use of prescription medications: how should emerging evidence of gabapentin misuse be addressed? ( Fairman, KA; Peckham, AM; Sclar, DA, 2018)
" Whereas chronic administration of the cannabinoid receptor agonist WIN55,212 (WIN) resulted in increased basal GABA release, the D2 agonist receptor-mediated control of GABA and DA release elicited by quinpirole was similar in both cannabinoid-dependent and non dependent animals."1.48Cannabinoid dependence induces sustained changes in GABA release in the globus pallidus without affecting dopamine release in the dorsal striatum: A dual microdialysis probe study. ( Decara, J; Edwards, S; Moreno, M; Parsons, LH; Pavon, FJ; Rodríguez de Fonseca, F; Serrano, A; Stouffer, DG; Suárez, J, 2018)
"Smoking polysubstance users were more impulsive than smokers, and both groups were more impulsive than controls."1.46Prefrontal Glx and GABA concentrations and impulsivity in cigarette smokers and smoking polysubstance users. ( Goudriaan, AE; Homberg, JR; Kaag, AM; Reneman, L; Schmaal, L; Schulte, MHJ; van den Brink, W; van Wingen, GA; Wiers, RW, 2017)
"Fifty-eight percent had an opioid use disorder, again mostly in combination with other drugs and/or alcohol."1.43Abuse of Gabapentin is Associated with Opioid Addiction. ( Bastiaens, L; Galus, J; Mazur, C, 2016)
" Its desired and adverse effects appear similar to other gamma-aminobutyric acid receptor agonists."1.43Phenibut (4-amino-3-phenyl-butyric acid): Availability, prevalence of use, desired effects and acute toxicity. ( Archer, JR; Dargan, PI; Owen, DR; Wood, DM, 2016)
" According to the grey literature, phenibut is taken for its anxiolytic and euphoric properties, with tolerance and withdrawal syndromes commonly reported adverse effects."1.43Phenibut (4-amino-3-phenyl-butyric acid): Availability, prevalence of use, desired effects and acute toxicity. ( Archer, JR; Dargan, PI; Owen, DR; Wood, DM, 2016)
" To gather information on prevalence of use, desired effects and/or adverse effects, we searched grey literature (online drug discussion forums) and medical literature (PubMed and abstracts from selected International Toxicology conferences)."1.43Phenibut (4-amino-3-phenyl-butyric acid): Availability, prevalence of use, desired effects and acute toxicity. ( Archer, JR; Dargan, PI; Owen, DR; Wood, DM, 2016)
"All patients had substance use disorders, the large majority (72 %) to more than one substance."1.43Abuse of Gabapentin is Associated with Opioid Addiction. ( Bastiaens, L; Galus, J; Mazur, C, 2016)
"Carisoprodol is a widely prescribed muscle relaxant, abuse of which has grown considerably in recent years."1.42Assessment of subunit-dependent direct gating and allosteric modulatory effects of carisoprodol at GABA(A) receptors. ( Dillon, GH; González, LA; Kumar, M, 2015)
"In the drug abuser cases, PRG poisoning represented 19."1.40Profiles of pregabalin and gabapentin abuse by postmortem toxicology. ( Gergov, M; Häkkinen, M; Kalso, E; Ojanperä, I; Vuori, E, 2014)
"Drug abuse was associated with 48."1.40Profiles of pregabalin and gabapentin abuse by postmortem toxicology. ( Gergov, M; Häkkinen, M; Kalso, E; Ojanperä, I; Vuori, E, 2014)
" Mean daily PRG dosage was 1424 mg."1.39Pregabalin abuse and dependence in Germany: results from a database query. ( Freudenmann, RW; Gahr, M; Hiemke, C; Kölle, MA; Schönfeldt-Lecuona, C, 2013)
"Some patients had no known history of substance abuse."1.38Gabapentin and pregabalin: abuse and addiction. ( , 2012)
"Gabapentin is a central nervous system inhibitory agent with likely gamma-aminobutyric acid (GABA)-ergic and non-GABAergic mechanisms of action."1.35Gabapentin-induced delirium and dependence. ( Kahn, DA; Kruszewski, SP; Paczynski, RP, 2009)
"Tolerance, dependence, and adverse effects on cognitive functions are well-known consequences of long-term use of benzodiazepines (BDZ), especially at high doses, raising thorny therapeutic problems in their discontinuation."1.35Pregabalin in the discontinuation of long-term benzodiazepines' use. ( Karakatsanis, NA; Karapoulios, E; Konstantakopoulos, G; Kontoangelos, KA; Kouzoupis, AV; Masdrakis, VG; Oulis, P; Papadimitriou, GN, 2008)
"Zolpidem is an imidazopyridine hypnotic that is believed to act selectively at alpha(1) subunit-containing gamma-aminobutyric acid type A (GABA(A)) receptors and thus to have minimal abuse and dependence potential."1.32Three cases of zolpidem dependence treated with fluoxetine: the serotonin hypothesis. ( Christodoulou, GN; Dimopoulos, NP; Gitsa, OE; Liappas, AI; Liappas, IA; Malitas, PN; Nikolaou, CK, 2003)
"Epilepsy is a common condition in people with learning disabilities with many patients continuing to suffer from seizures despite antiepileptic drug (AED) treatment."1.30A naturalistic study of the use of vigabatrin, lamotrigine and gabapentin in adults with learning disabilities. ( Bhaumik, S; Branford, D; Duggirala, C; Ismail, IA, 1997)
"Lamotrigine caused increased seizures in 24% of patients, especially when prescribed at a higher dose."1.30A naturalistic study of the use of vigabatrin, lamotrigine and gabapentin in adults with learning disabilities. ( Bhaumik, S; Branford, D; Duggirala, C; Ismail, IA, 1997)
" In the test of physical dependence-producing potential with the drug-admixed food method in rats, vigabatrin and diazepam were given to rats mixed with food for 28 days in an increasing dosage schedule, followed by feeding a drug-free diet to observe withdrawal signs for 7 days."1.30Drug dependence study on vigabatrin in rhesus monkeys and rats. ( Takada, K; Yanagita, T, 1997)
"Vigabatrin proved to be a potent anticonvulsant drug at acute doses (100-200 mg/kg), but during chronic administration, the anticonvulsant activity of the treatment was lost already in the second week of treatment."1.28Development of tolerance to the anticonvulsant effect of vigabatrin in amygdala-kindled rats. ( Löscher, W; Rundfeldt, C, 1992)
"Buspirone is a clinically effective anxiolytic with a unique structure and pharmacology which distinguishes it from the benzodiazepines."1.27Neuropharmacology of buspirone. ( Eison, AS; Eison, MS; Riblet, LA; Taylor, DP; Temple, DL; VanderMaelen, CP, 1984)
" Prevention is easy if treatment is gradually rather than abruptly withdrawn in all patients who receive the compound in high dosage for more than one month."1.26[Benzodiazepine physical dependence. 6 cases (author's transl)]. ( Bismuth, C; Dally, S; Lagier, G; Le Bellec, M, 1980)
"Rats exposed to chronic intake of sodium barbital maintained high circulating levels of barbital in blood and brain and exhibited increased sensitivity ot audiogenic convulsions during the withdrawal period."1.26Changes in brain levels of cyclic nucleotides and gamma-aminobutyric acid in barbiturate dependence and withdrawal. ( Hawkins, TD; Kant, GJ; Lenox, RH; Meyerhoff, JL; Wray, HL, 1979)

Research

Studies (167)

TimeframeStudies, this research(%)All Research%
pre-199025 (14.97)18.7374
1990's19 (11.38)18.2507
2000's36 (21.56)29.6817
2010's74 (44.31)24.3611
2020's13 (7.78)2.80

Authors

AuthorsStudies
Tran, MN1
Maynard, KR1
Spangler, A1
Huuki, LA1
Montgomery, KD1
Sadashivaiah, V1
Tippani, M1
Barry, BK1
Hancock, DB1
Hicks, SC1
Kleinman, JE1
Hyde, TM1
Collado-Torres, L1
Jaffe, AE1
Martinowich, K1
Subramaniam, P1
Prescot, A1
McGlade, E1
Renshaw, P1
Yurgelun-Todd, D1
Di Ciano, P1
Hendershot, CS1
Le Foll, B1
Wainblat, E1
Weleff, J1
Anand, A1
Burkat, PM1
Nudmamud-Thanoi, S1
Veerasakul, S1
Thanoi, S1
Kokane, SS1
Armant, RJ1
Bolaños-Guzmán, CA1
Perrotti, LI1
Kupats, E1
Vrublevska, J1
Zvejniece, B1
Vavers, E1
Stelfa, G1
Zvejniece, L1
Dambrova, M1
Barker, JS1
Hines, RM1
López-Gambero, AJ1
Rodríguez de Fonseca, F2
Suárez, J2
Mash, JE1
Leo, RJ1
Li, X1
Slesinger, PA1
Doyno, CR1
White, CM1
Peckham, AM2
Fairman, KA2
Sclar, DA2
Buttram, ME1
Kurtz, SP1
Dart, RC1
Margolin, ZR1
Joshi, YB1
Friend, SF1
Jimenez, B1
Steiger, LR1
Schulte, MHJ1
Kaag, AM1
Wiers, RW1
Schmaal, L1
van den Brink, W1
Reneman, L1
Homberg, JR1
van Wingen, GA1
Goudriaan, AE1
Heeren, N1
Farver, D1
Bonnet, U2
Scherbaum, N3
Puhl, MD1
Desai, RI1
Takagi, S1
Presti, KT1
Doyle, MR1
Donahue, RJ1
Landino, SM1
Bergman, J1
Carlezon, WA1
Coyle, JT1
Throckmorton, DC1
Gottlieb, S1
Woodcock, J1
Richter, EL1
Isbruch, K1
Tomko, JR1
Prasad, KM1
Kubas, S1
Simpson, T1
Moreno, M1
Decara, J1
Pavon, FJ1
Stouffer, DG2
Edwards, S1
Serrano, A1
Parsons, LH2
Hardman, MI1
Sprung, J1
Weingarten, TN1
Jouney, EA1
Konen, C1
Niederst, E1
Westin, AA3
Bramness, JG2
Chalabianloo, F2
Rygnestad, T1
Slørdal, L2
Cruz, MT1
Bajo, M1
Schweitzer, P1
Roberto, M2
Kumar, K1
Sharma, S1
Kumar, P2
Deshmukh, R1
Grosshans, M2
Lemenager, T1
Vollmert, C1
Kaemmerer, N1
Schreiner, R1
Mutschler, J2
Wagner, X1
Kiefer, F2
Hermann, D2
Rohman, L1
Hebron, A1
Bodén, R1
Wettermark, B1
Brandt, L1
Kieler, H1
Baird, CR1
Fox, P1
Colvin, LA1
Oulis, P3
Kalogerakou, S1
Anyfandi, E1
Konstantakopoulos, G3
Papakosta, VM1
Masdrakis, V1
Tsaltas, E1
Howland, RH2
O'Connell, CW1
Schneir, AB1
Hwang, JQ1
Cantrell, FL1
Schifano, F3
Cho, YW1
Song, ML1
Häkkinen, M1
Vuori, E1
Kalso, E1
Gergov, M1
Ojanperä, I1
Papazisis, G1
Tzachanis, D1
Aligny, C1
Roux, C1
Dourmap, N1
Ramdani, Y1
Do-Rego, JC1
Jégou, S1
Leroux, P1
Leroux-Nicollet, I1
Marret, S1
Gonzalez, BJ1
Davydova, TV1
Vetrile, LA1
Nevidimova, TI1
Vetlugina, TP1
Fomina, VG1
Zakharova, IA1
Batukhtina, EI1
Bokhan, NA1
Jonsson, B1
Backman, E1
Salmonson, H1
Höjer, J1
Kumar, M1
González, LA1
Dillon, GH1
Smith, RV2
Lofwall, MR1
Havens, JR2
Moeller, SJ1
London, ED1
Northoff, G1
Owen, DR1
Wood, DM1
Archer, JR1
Dargan, PI1
Mersfelder, TL1
Nichols, WH1
Barker, DJ1
Root, DH1
Zhang, S1
Morales, M1
Izumi, Y1
Zorumski, CF1
Bastiaens, L1
Galus, J1
Mazur, C1
Mariani, JJ1
Malcolm, RJ2
Mamczur, AK1
Choi, JC1
Brady, R1
Nunes, E1
Levin, FR1
Walsh, SL1
Chiappini, S1
Evoy, KE1
Morrison, MD1
Saklad, SR1
Ferré, S1
Quiroz, C1
Woods, AS1
Cunha, R1
Popoli, P1
Ciruela, F1
Lluis, C1
Franco, R1
Azdad, K1
Schiffmann, SN1
Forde, G1
Stanos, S1
Apgar, BS1
Uhart, M1
Wand, GS1
Heberlein, A1
Bleich, S1
Kornhuber, J1
Hillemacher, T1
Schjøtt, J1
Mondón, S1
Nogué, S1
Urbano, D1
Rovira, E1
Xi, ZX1
Gardner, EL1
Kruszewski, SP1
Paczynski, RP1
Kahn, DA1
Conner, BT1
Hellemann, GS1
Ritchie, TL1
Noble, EP1
Raza, S1
Siddiqui, UA1
Megna, JL1
Schwartz, TL1
Batki, SL1
Rawls, SM1
Patil, T1
Yuvasheva, E1
Raffa, RB1
Schwan, S1
Sundström, A1
Stjernberg, E1
Hallberg, E1
Hallberg, P1
Klein, O1
Dressing, H1
Mann, K1
Caster, O1
Edwards, IR1
Norén, GN1
Lindquist, M1
Strøm, EJ2
Filipetto, FA1
Zipp, CP1
Coren, JS1
Kurokawa, K1
Shibasaki, M1
Mizuno, K1
Ohkuma, S1
D'Offizi, S1
Piccione, M1
Corazza, O1
Deluca, P1
Davey, Z1
Di Melchiorre, G1
Di Furia, L1
Farré, M1
Flesland, L1
Mannonen, M1
Majava, A1
Pagani, S1
Peltoniemi, T1
Siemann, H1
Skutle, A1
Torrens, M1
Pezzolesi, C1
van der Kreeft, P1
Landmark, CJ2
Fossmark, H1
Larsson, PG2
Rytter, E2
Johannessen, SI2
Helland, A2
Rubio, G1
Bobes, J1
Cervera, G1
Terán, A1
Pérez, M1
López-Gómez, V1
Rejas, J1
Changeux, JP1
Lou, HC1
Barrot, M1
Thome, J1
Addolorato, G1
Leggio, L1
Hopf, FW1
Diana, M1
Bonci, A1
Zacny, JP1
Paice, JA1
Coalson, DW1
Conesa, ML1
Rojo, LM1
Plumed, J1
Livianos, L1
Schroll, J1
Martinotti, G1
Shameem, M1
Patel, AB1
Leach, JP1
Mohanraj, R1
Borland, W1
Gahr, M1
Freudenmann, RW1
Hiemke, C1
Kölle, MA1
Schönfeldt-Lecuona, C1
Persheim, MS1
Spigset, O1
Samokhvalov, AV1
Paton-Gay, CL1
Balchand, K1
Rehm, J1
Liappas, IA1
Malitas, PN1
Dimopoulos, NP1
Gitsa, OE1
Liappas, AI1
Nikolaou, CK1
Christodoulou, GN1
Voris, J1
Smith, NL1
Rao, SM1
Thorne, DL1
Flowers, QJ1
Hu, JH1
Yang, N1
Ma, YH1
Zhou, XG1
Jiang, J1
Duan, SH1
Mei, ZT1
Fei, J1
Guo, LH1
Jain, MK1
Vik, PW1
Cellucci, T1
Jarchow, A1
Hedt, J1
Ikemoto, S1
Wise, RA1
Petit, TL1
Madamba, SG1
Siggins, GR1
Palomo, T1
Kostrzewa, RM1
Beninger, RJ1
Archer, T1
Berghuis, P1
Dobszay, MB1
Wang, X1
Spano, S1
Ledda, F1
Sousa, KM1
Schulte, G1
Ernfors, P1
Mackie, K1
Paratcha, G1
Hurd, YL1
Harkany, T1
Crunelli, V1
Emri, Z1
Leresche, N1
Laviolette, SR1
Grace, AA1
Heinzerling, KG1
Shoptaw, S1
Peck, JA1
Yang, X1
Liu, J1
Roll, J1
Ling, W1
Amin, Z1
Mason, GF1
Cavus, I1
Krystal, JH1
Rothman, DL1
Epperson, CN1
Victorri-Vigneau, C1
Guerlais, M1
Jolliet, P1
Nugent, FS1
Penick, EC1
Kauer, JA1
Brewer, JA1
Potenza, MN1
Howell, LL1
Kimmel, HL1
Urschel, HC1
Hanselka, LL1
Gromov, I1
White, L1
Baron, M1
Torregrossa, MM1
Kalivas, PW1
Klempan, TA1
Sequeira, A1
Canetti, L1
Lalovic, A1
Ernst, C1
ffrench-Mullen, J1
Turecki, G1
Kouzoupis, AV1
Masdrakis, VG1
Karakatsanis, NA1
Karapoulios, E1
Kontoangelos, KA1
Papadimitriou, GN1
DeFeudis, FV1
Bismuth, C1
Le Bellec, M1
Dally, S1
Lagier, G1
Carranza, J1
Danneberg, P1
Weber, KH1
Haefely, W1
Riblet, LA1
Eison, AS1
Eison, MS1
Taylor, DP1
Temple, DL1
VanderMaelen, CP1
Nabeshima, T1
Furukawa, H1
Kameyama, T1
Lorini, G1
Fazio, L1
Fusari, A1
Cocchi, R3
Schoffelmeer, AN1
De Vries, TJ1
Vanderschuren, LJ1
Tjon, GH1
Nestby, P1
Wardeh, G1
Mulder, AH1
Nabeshima, A2
Saito, T3
Takahata, N3
Toki, S2
Fricchione, GL1
Mendoza, A1
Stefano, GB1
White, FJ1
Hatta, S1
Maitre, M1
Javitt, DC1
Frusciante, M1
Bhaumik, S1
Branford, D1
Duggirala, C1
Ismail, IA1
Markowitz, JS2
Finkenbine, R1
Myrick, H1
King, L1
Carson, WH1
Koob, GF2
Takada, K1
Yanagita, T1
Bernasconi, R1
Mathivet, P1
Bischoff, S1
Marescaux, C1
Letterman, L1
Scearce-Levie, K1
Chen, JP1
Gardner, E1
Hen, R1
Collier, DA1
Ciccocioppo, R1
Angeletti, S1
Panocka, I1
Massi, M1
Crockford, D1
White, WD1
Campbell, B1
Cousins, MS1
Roberts, DC1
de Wit, H1
Tornati, A2
Gourley, DR1
Lenox, RH1
Wray, HL1
Kant, GJ1
Hawkins, TD1
Meyerhoff, JL1
Rix, KJ1
Davidson, N1
Brase, DA1
Sytinsky, IA1
Galebskaya, LV1
Magelund, CG1
Mørck, HI1
Iwata, H1
Matsuda, T1
Yamagami, S1
Hirata, Y1
Baba, A1
Contreras, E1
Tamayo, L1
Quijada, L1
Ho, IK2
Loh, HH1
Way, EL1
Rundfeldt, C1
Löscher, W1
Hughes, J1
Hunter, JC1
Woodruff, GN1
Saunders, PA1
Taberner, PV2
Liljequist, S1
Culp, S1
Tabakoff, B1
Goodwin, FK1
Gray, PL1
Drugan, RC1
Maier, SF1
Ziltman, FG1

Clinical Trials (7)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Erenumab as a Therapeutic Approach for the Management of Painful Chronic Temporomandibular Disorders (TMD)[NCT05162027]Phase 25 participants (Actual)Interventional2022-04-01Terminated (stopped due to Low enrollment rate)
Efficacy of Gabapentin for Post-Covid-19 Olfactory Dysfunction[NCT05184192]Phase 250 participants (Anticipated)Interventional2022-01-10Enrolling by invitation
A Randomized Controlled Pilot Trial of Gabapentin for the Treatment of Benzodiazepine Abuse in Methadone Maintenance Patients[NCT00420771]Phase 219 participants (Actual)Interventional2007-01-31Completed
Gabapentin Regimens and Their Effects on Opioid Consumption[NCT03334903]Phase 477 participants (Actual)Interventional2018-05-15Completed
Pharmacogenetic Treatment With Anti-Glutaminergic Agents for Comorbid PTSD & AUD[NCT02884908]Phase 3252 participants (Anticipated)Interventional2016-09-30Active, not recruiting
A Post Marketing Study to Evaluate the Safety and Efficacy of Endourage Complete Spectrum Oral Mucosal Drops (OMD) in Adults Desiring a Reduction in Ethanol Use[NCT04659278]0 participants (Actual)Interventional2021-09-30Withdrawn (stopped due to Study has been placed on hold)
fMRI Study of a Dual Process Treatment Protocol With Substance Dependent Adults[NCT01320748]29 participants (Actual)Interventional2011-02-28Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Mean Reduction Change in Benzodiazepine Use Per Day Based on Time Line Follow Back

Comparing the mean reduction change in Benzodiazepine use per day when comparing the baseline week prior to study entry to the last week of study participation based on the Time Line Follow Back (NCT00420771)
Timeframe: data collected during 8 weeks of trial or length of participation

Interventionmilligrams/day (Mean)
Active Medication4.0
Placebo2.3

"VAS Score 1: How Much Pain do You Feel in Your Operative Site When Resting?"

Surgical site pain. Scale 0-10, with 0 best and 10 worst (NCT03334903)
Timeframe: 2-3 months after surgery (at 2nd postoperative appointment)

Interventionscore on 10-point scale (Mean)
Standard of Care2.26
Postoperative Gabapentin Regimen2.46

"VAS Score 2: How Much Pain do You Feel in Your Operative Site When Moving?"

Surgical site pain. Scale 0-10, with 0 best and 10 worst. (NCT03334903)
Timeframe: 2-3 months following surgery (measured at second postoperative appointment).

Interventionscore on a 10-point scale (Mean)
Standard of Care3.84
Postoperative Gabapentin Regimen3.54

"VAS Score 3: How Well Are You Sleeping?"

Sleep quality. Scale 0-10 with 0 worst and 10 best. (NCT03334903)
Timeframe: 2-3 months following surgery (measured at second postoperative appointment).

Interventionscore on a 10-point scale (Mean)
Standard of Care5.73
Postoperative Gabapentin Regimen6.38

"VAS Score 4: How Bad is Your Nausea?"

Nausea. Scale 0-10, with 0 best and 10 worst. (NCT03334903)
Timeframe: 2-3 months following surgery (measured at second postoperative appointment).

Interventionscore on a 10-point scale (Mean)
Standard of Care0.36
Postoperative Gabapentin Regimen0.17

"VAS Score 5: How Satisfied Are You With Your Pain Management?"

Satisfaction. Scale 0-10 with 0 worst and 10 best. (NCT03334903)
Timeframe: 2-3 months following surgery (measured at second postoperative appointment).

Interventionscore on a 10-point scale (Mean)
Standard of Care7.83
Postoperative Gabapentin Regimen8.48

Days Taking Opioids

Number of days until patients are finished consuming opioid medications after discharge. (NCT03334903)
Timeframe: 2-3 months following surgery (measured at second postoperative appointment).

Interventiondays (Mean)
Standard of Care14.8
Postoperative Gabapentin Regimen18.7

Opioid Consumption

Mean opioid consumption, measured in mg of morphine equivalents. (NCT03334903)
Timeframe: 2-3 months following surgery (total amount measured at second postoperative appointment; means assessed afterwards).

Interventionmorphine equivalents (Mean)
Standard of Care287.0
Postoperative Gabapentin Regimen281.1

Reviews

57 reviews available for gamma-aminobutyric acid and Chemical Dependence

ArticleYear
Therapeutic Potential of Histamine H3 Receptors in Substance Use Disorders.
    Current topics in behavioral neurosciences, 2022, Volume: 59

    Topics: Acetylcholine; Animals; Autoreceptors; Central Nervous System Stimulants; Dopamine; Ethanol; gamma-A

2022
Pharmacogenetics of drug dependence: Polymorphisms of genes involved in GABA neurotransmission.
    Neuroscience letters, 2020, 05-01, Volume: 726

    Topics: Animals; gamma-Aminobutyric Acid; Humans; Pharmacogenetics; Polymorphism, Single Nucleotide; Recepto

2020
Overlap in the neural circuitry and molecular mechanisms underlying ketamine abuse and its use as an antidepressant.
    Behavioural brain research, 2020, 04-20, Volume: 384

    Topics: Antidepressive Agents; Brain; Cholinergic Neurons; Depressive Disorder, Major; Depressive Disorder,

2020
Safety and Tolerability of the Anxiolytic and Nootropic Drug Phenibut: A Systematic Review of Clinical Trials and Case Reports.
    Pharmacopsychiatry, 2020, Volume: 53, Issue:5

    Topics: Anti-Anxiety Agents; gamma-Aminobutyric Acid; Humans; Nootropic Agents; Substance-Related Disorders

2020
Regulation of GABA
    International journal of molecular sciences, 2020, Jun-22, Volume: 21, Issue:12

    Topics: Animals; gamma-Aminobutyric Acid; Gene Expression Regulation; Humans; Protein Subunits; Receptors, G

2020
Energy sensors in drug addiction: A potential therapeutic target.
    Addiction biology, 2021, Volume: 26, Issue:2

    Topics: AMP-Activated Protein Kinases; Brain; Dopamine; Dopaminergic Neurons; G Protein-Coupled Inwardly-Rec

2021
How addictive are gabapentin and pregabalin? A systematic review.
    European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 2017, Volume: 27, Issue:12

    Topics: Amines; Analgesics; Behavior, Addictive; Cyclohexanecarboxylic Acids; Databases, Bibliographic; Drug

2017
On the addictive power of gabapentinoids: a mini-review.
    Psychiatria Danubina, 2018, Volume: 30, Issue:2

    Topics: Adult; Amines; Animals; Comorbidity; Craving; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobu

2018
Acute phenibut withdrawal: A comprehensive literature review and illustrative case report.
    Bosnian journal of basic medical sciences, 2019, May-20, Volume: 19, Issue:2

    Topics: Akathisia, Drug-Induced; Baclofen; Cyproheptadine; Dexmedetomidine; Diphenhydramine; GABA-A Receptor

2019
Phenibut (β-Phenyl-γ-Aminobutyric Acid): an Easily Obtainable "Dietary Supplement" With Propensities for Physical Dependence and Addiction.
    Current psychiatry reports, 2019, 03-09, Volume: 21, Issue:4

    Topics: Behavior, Addictive; Dietary Supplements; gamma-Aminobutyric Acid; Humans; Hypnotics and Sedatives;

2019
Shared mechanisms of alcohol and other drugs.
    Alcohol research & health : the journal of the National Institute on Alcohol Abuse and Alcoholism, 2008, Volume: 31, Issue:2

    Topics: Alcohol Drinking; Alcoholism; Analgesics, Opioid; Animals; Cannabinoids; gamma-Aminobutyric Acid; Hu

2008
Therapeutic potential of GABA(B) receptor ligands in drug addiction, anxiety, depression and other CNS disorders.
    Pharmacology, biochemistry, and behavior, 2013, Volume: 110

    Topics: Anxiety; Central Nervous System Diseases; Depression; GABA Modulators; gamma-Aminobutyric Acid; Huma

2013
Gabapentin for the treatment of substance use disorders.
    Journal of psychosocial nursing and mental health services, 2013, Volume: 51, Issue:12

    Topics: Amines; Antimanic Agents; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid; Humans;

2013
Misuse and abuse of pregabalin and gabapentin: cause for concern?
    CNS drugs, 2014, Volume: 28, Issue:6

    Topics: Amines; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid; Humans; Pregabalin; Prescr

2014
Pregabalin's abuse potential: a mini review focusing on the pharmacological profile.
    International journal of clinical pharmacology and therapeutics, 2014, Volume: 52, Issue:8

    Topics: Analgesics; Animals; Behavior, Addictive; gamma-Aminobutyric Acid; Humans; Neurons; Practice Pattern

2014
Neuroimaging markers of glutamatergic and GABAergic systems in drug addiction: Relationships to resting-state functional connectivity.
    Neuroscience and biobehavioral reviews, 2016, Volume: 61

    Topics: Animals; Brain; Brain Mapping; gamma-Aminobutyric Acid; Glutamic Acid; Humans; Neuroimaging; Substan

2016
Gabapentin: Abuse, Dependence, and Withdrawal.
    The Annals of pharmacotherapy, 2016, Volume: 50, Issue:3

    Topics: Amines; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid; Humans; Substance Abuse Tr

2016
Gabapentin: Abuse, Dependence, and Withdrawal.
    The Annals of pharmacotherapy, 2016, Volume: 50, Issue:3

    Topics: Amines; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid; Humans; Substance Abuse Tr

2016
Gabapentin: Abuse, Dependence, and Withdrawal.
    The Annals of pharmacotherapy, 2016, Volume: 50, Issue:3

    Topics: Amines; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid; Humans; Substance Abuse Tr

2016
Gabapentin: Abuse, Dependence, and Withdrawal.
    The Annals of pharmacotherapy, 2016, Volume: 50, Issue:3

    Topics: Amines; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid; Humans; Substance Abuse Tr

2016
Multiplexed neurochemical signaling by neurons of the ventral tegmental area.
    Journal of chemical neuroanatomy, 2016, Volume: 73

    Topics: Animals; Behavior; Depression; Dopamine; gamma-Aminobutyric Acid; Habenula; Humans; Neurons; Neurotr

2016
Gabapentin misuse, abuse and diversion: a systematic review.
    Addiction (Abingdon, England), 2016, Volume: 111, Issue:7

    Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid; Humans; Prescr

2016
Abuse and Misuse of Pregabalin and Gabapentin.
    Drugs, 2017, Volume: 77, Issue:4

    Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Drug Overdose; Gabapentin; gamma-Aminobutyric Acid;

2017
An update on adenosine A2A-dopamine D2 receptor interactions: implications for the function of G protein-coupled receptors.
    Current pharmaceutical design, 2008, Volume: 14, Issue:15

    Topics: Adenosine A2 Receptor Agonists; Adenosine A2 Receptor Antagonists; Adenylyl Cyclases; Animals; Basal

2008
Practical management strategies for the chronic pain patient.
    The Journal of family practice, 2007, Volume: 56, Issue:8 Suppl Ho

    Topics: Administration, Cutaneous; Amines; Analgesics; Antidepressive Agents, Tricyclic; Carbamazepine; Chro

2007
Stress, alcohol and drug interaction: an update of human research.
    Addiction biology, 2009, Volume: 14, Issue:1

    Topics: Alcoholism; Allostasis; Animals; Arousal; Brain; Corticotropin-Releasing Hormone; Cues; Dopamine; ga

2009
[Benzodiazepine dependence: causalities and treatment options].
    Fortschritte der Neurologie-Psychiatrie, 2009, Volume: 77, Issue:1

    Topics: Animals; Benzodiazepines; Corticotropin-Releasing Hormone; gamma-Aminobutyric Acid; Humans; Hypnotic

2009
[Pregabalin and its potential for abuse].
    Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke, 2009, Jan-29, Volume: 129, Issue:3

    Topics: Analgesics; gamma-Aminobutyric Acid; Humans; Pregabalin; Risk Factors; Substance-Related Disorders

2009
Hypothesis-driven medication discovery for the treatment of psychostimulant addiction.
    Current drug abuse reviews, 2008, Volume: 1, Issue:3

    Topics: Animals; Brain; Cannabinoid Receptor Modulators; Central Nervous System Stimulants; Cocaine-Related

2008
Pregabalin in the treatment of alcohol and benzodiazepines dependence.
    CNS neuroscience & therapeutics, 2010,Spring, Volume: 16, Issue:1

    Topics: Alcoholism; Anticonvulsants; Benzodiazepines; gamma-Aminobutyric Acid; Humans; Pregabalin; Substance

2010
Emergent pharmacology of conscious experience: new perspectives in substance addiction.
    FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2011, Volume: 25, Issue:7

    Topics: Animals; Brain; Consciousness; GABA Modulators; gamma-Aminobutyric Acid; Humans; Models, Neurologica

2011
Discovering a new anatomical structure in the brain: implications for neuropsychiatry and therapy.
    The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry, 2011, Volume: 12 Suppl 1

    Topics: Animals; Arousal; Brain; Brain Mapping; Diffusion Magnetic Resonance Imaging; Dopamine; Drug Deliver

2011
Novel therapeutic strategies for alcohol and drug addiction: focus on GABA, ion channels and transcranial magnetic stimulation.
    Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2012, Volume: 37, Issue:1

    Topics: Alcoholism; Brain Chemistry; gamma-Aminobutyric Acid; Humans; Ion Channels; Substance-Related Disord

2012
Alcohol and drugs in epilepsy: pathophysiology, presentation, possibilities, and prevention.
    Epilepsia, 2012, Volume: 53 Suppl 4

    Topics: Alcohol Drinking; Alcohol Withdrawal Seizures; Alcoholism; Amphetamine-Related Disorders; Benzodiaze

2012
Cognitive impairment in substance abuse.
    The Psychiatric clinics of North America, 2004, Volume: 27, Issue:1

    Topics: Alcohol Amnestic Disorder; Amphetamines; Central Nervous System Stimulants; Cognition Disorders; Eth

2004
Mapping of chemical trigger zones for reward.
    Neuropharmacology, 2004, Volume: 47 Suppl 1

    Topics: Acetylcholine; Animals; Behavior, Animal; Brain; Brain Mapping; Carbachol; Dopamine; Drug Delivery S

2004
Gene-environment interplay in alcoholism and other substance abuse disorders: expressions of heritability and factors influencing vulnerability.
    Neurotoxicity research, 2004, Volume: 6, Issue:5

    Topics: Alcoholism; Biogenic Monoamines; Event-Related Potentials, P300; gamma-Aminobutyric Acid; Humans; Pe

2004
Unravelling the brain targets of gamma-hydroxybutyric acid.
    Current opinion in pharmacology, 2006, Volume: 6, Issue:1

    Topics: Animals; Brain; Epilepsy, Absence; GABA-B Receptor Agonists; gamma-Aminobutyric Acid; Humans; Hydrox

2006
The roles of cannabinoid and dopamine receptor systems in neural emotional learning circuits: implications for schizophrenia and addiction.
    Cellular and molecular life sciences : CMLS, 2006, Volume: 63, Issue:14

    Topics: Amygdala; Animals; Appetitive Behavior; Arachidonic Acids; Association Learning; Cannabinoids; Centr

2006
The interaction of neuroactive steroids and GABA in the development of neuropsychiatric disorders in women.
    Pharmacology, biochemistry, and behavior, 2006, Volume: 84, Issue:4

    Topics: Affect; Depression, Postpartum; Female; gamma-Aminobutyric Acid; Humans; Menstruation; Mental Disord

2006
The neurobiology and genetics of impulse control disorders: relationships to drug addictions.
    Biochemical pharmacology, 2008, Jan-01, Volume: 75, Issue:1

    Topics: Animals; Decision Making; Disruptive, Impulse Control, and Conduct Disorders; Dopamine; Endorphins;

2008
Monoamine transporters and psychostimulant addiction.
    Biochemical pharmacology, 2008, Jan-01, Volume: 75, Issue:1

    Topics: Animals; Central Nervous System Stimulants; Conditioning, Operant; Dopamine Plasma Membrane Transpor

2008
Microdialysis and the neurochemistry of addiction.
    Pharmacology, biochemistry, and behavior, 2008, Volume: 90, Issue:2

    Topics: Animals; Dopamine; gamma-Aminobutyric Acid; Glutamic Acid; Microdialysis; Neuronal Plasticity; Serot

2008
Chemical structure and biological activity of the diazepines.
    British journal of clinical pharmacology, 1983, Volume: 16 Suppl 2

    Topics: Acetylcholine; Aggression; Animals; Anti-Anxiety Agents; Anxiety; Autonomic Nervous System; Behavior

1983
[Phencyclidine, a drug which induces psychosis: its neuropharmacological actions].
    Yakubutsu, seishin, kodo = Japanese journal of psychopharmacology, 1984, Volume: 4, Issue:2

    Topics: Acetylcholine; Animals; Behavior, Animal; Binding Sites; Brain; Cats; Dogs; Dopamine; Drug Tolerance

1984
Morphine and its psychiatric implications.
    Advances in neuroimmunology, 1994, Volume: 4, Issue:2

    Topics: Animals; Anxiety, Separation; Cathexis; Dopamine; gamma-Aminobutyric Acid; Gene Expression Regulatio

1994
Synaptic regulation of mesocorticolimbic dopamine neurons.
    Annual review of neuroscience, 1996, Volume: 19

    Topics: Afferent Pathways; Animals; Antipsychotic Agents; Dopamine; Excitatory Amino Acids; gamma-Aminobutyr

1996
The gamma-hydroxybutyrate signalling system in brain: organization and functional implications.
    Progress in neurobiology, 1997, Volume: 51, Issue:3

    Topics: Animals; Brain; gamma-Aminobutyric Acid; Humans; Mammals; Models, Neurological; Rats; Receptors, GAB

1997
Drug abuse and alcoholism. Overview.
    Advances in pharmacology (San Diego, Calif.), 1998, Volume: 42

    Topics: Alcoholism; Animals; Brain; Cocaine; Dopamine; Emotions; gamma-Aminobutyric Acid; Humans; Membrane G

1998
Circuits, drugs, and drug addiction.
    Advances in pharmacology (San Diego, Calif.), 1998, Volume: 42

    Topics: Amygdala; Animals; Benzazepines; Brain; Cocaine; Dextroamphetamine; Dopamine; gamma-Aminobutyric Aci

1998
Gabapentin: a review of published experience in the treatment of bipolar disorder and other psychiatric conditions.
    Pharmacotherapy, 1999, Volume: 19, Issue:5

    Topics: Acetates; Amines; Anticonvulsants; Anxiety; Bipolar Disorder; Cyclohexanecarboxylic Acids; Gabapenti

1999
Nociceptin/orphanin FQ and drugs of abuse.
    Peptides, 2000, Volume: 21, Issue:7

    Topics: Alcohol Drinking; Analgesics, Opioid; Animals; Behavior; Brain; Dopamine; gamma-Aminobutyric Acid; G

2000
GABA(B) receptor agonists for the treatment of drug addiction: a review of recent findings.
    Drug and alcohol dependence, 2002, Feb-01, Volume: 65, Issue:3

    Topics: Animals; Baclofen; Brain; Dopamine; GABA Agonists; GABA-B Receptor Agonists; gamma-Aminobutyric Acid

2002
Isolation and characterization of membrane drug receptors.
    Progress in drug research. Fortschritte der Arzneimittelforschung. Progres des recherches pharmaceutiques, 1976, Volume: 20

    Topics: Animals; Drug Tolerance; gamma-Aminobutyric Acid; Glucagon; Glycine; Humans; Insulin; Insulin Resist

1976
gamma-aminobutyric acid in alcohol, barbiturate and morphine dependence: a review.
    The British journal of addiction to alcohol and other drugs, 1977, Volume: 72, Issue:2

    Topics: Alcoholism; Aminobutyrates; Animals; Barbiturates; Brain; Ethanol; gamma-Aminobutyric Acid; Humans;

1977
Roles of serotonin and gamma-aminobutyric acid in opioid effects.
    Advances in biochemical psychopharmacology, 1979, Volume: 20

    Topics: Analgesia; Analgesics; Body Temperature Regulation; Drug Tolerance; Electric Stimulation; gamma-Amin

1979
Neurochemical actions of CCK underlying the therapeutic potential of CCK-B antagonists.
    Neuropeptides, 1991, Volume: 19 Suppl

    Topics: Animals; Anti-Anxiety Agents; Anxiety; Brain; Cholecystokinin; gamma-Aminobutyric Acid; Indoles; Meg

1991
Barbiturates and the GABAA receptor complex.
    Progress in drug research. Fortschritte der Arzneimittelforschung. Progres des recherches pharmaceutiques, 1990, Volume: 34

    Topics: Animals; Barbiturates; Drug Tolerance; gamma-Aminobutyric Acid; Humans; Receptors, GABA-A; Substance

1990
The GABA system in functional tolerance and dependence following barbiturates, benzodiazepines or ethanol--correlation or causality?
    Comparative biochemistry and physiology. A, Comparative physiology, 1989, Volume: 93, Issue:1

    Topics: Alcoholism; Animals; Barbiturates; Benzodiazepines; Drug Tolerance; gamma-Aminobutyric Acid; Neurons

1989
Control vs. lack of control over aversive stimuli: nonopioid-opioid analgesic consequences.
    NIDA research monograph, 1986, Volume: 74

    Topics: Analgesia; Animals; Electroshock; gamma-Aminobutyric Acid; Humans; Internal-External Control; Models

1986

Trials

6 trials available for gamma-aminobutyric acid and Chemical Dependence

ArticleYear
Effects of pregabalin in patients with hypnotic-dependent insomnia.
    Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine, 2014, May-15, Volume: 10, Issue:5

    Topics: Female; gamma-Aminobutyric Acid; Humans; Hypnotics and Sedatives; Male; Middle Aged; Pregabalin; Sle

2014
Pilot trial of gabapentin for the treatment of benzodiazepine abuse or dependence in methadone maintenance patients.
    The American journal of drug and alcohol abuse, 2016, Volume: 42, Issue:3

    Topics: Adolescent; Adult; Aged; Amines; Benzodiazepines; Combined Modality Therapy; Cyclohexanecarboxylic A

2016
Effects of pregabalin on subjective sleep disturbance symptoms during withdrawal from long-term benzodiazepine use.
    European addiction research, 2011, Volume: 17, Issue:5

    Topics: Adult; Anti-Anxiety Agents; Anxiety; Benzodiazepines; Female; gamma-Aminobutyric Acid; Humans; Male;

2011
Subjective, psychomotor, and physiological effects of pregabalin alone and in combination with oxycodone in healthy volunteers.
    Pharmacology, biochemistry, and behavior, 2012, Volume: 100, Issue:3

    Topics: Adult; Analgesics; Analgesics, Opioid; Anticonvulsants; Cross-Over Studies; Dose-Response Relationsh

2012
Gabapentin in the management of pentazocine dependence: a potent analgesic--anticraving agent.
    The Journal of the Association of Physicians of India, 2003, Volume: 51

    Topics: Acetates; Amines; Analgesics; Analgesics, Opioid; Anti-Anxiety Agents; Clonidine; Cyclohexanecarboxy

2003
Randomized, placebo-controlled trial of baclofen and gabapentin for the treatment of methamphetamine dependence.
    Drug and alcohol dependence, 2006, Dec-01, Volume: 85, Issue:3

    Topics: Adult; Amines; Anti-Anxiety Agents; Baclofen; Central Nervous System Stimulants; Cyclohexanecarboxyl

2006

Other Studies

104 other studies available for gamma-aminobutyric acid and Chemical Dependence

ArticleYear
Single-nucleus transcriptome analysis reveals cell-type-specific molecular signatures across reward circuitry in the human brain.
    Neuron, 2021, 10-06, Volume: 109, Issue:19

    Topics: Brain; Brain Mapping; Cell Nucleus; gamma-Aminobutyric Acid; Gene Expression Profiling; Genome-Wide

2021
Examination of gamma-aminobutyric acid and glutamate-glutamine levels in association with impulsive behavior in adolescent marijuana users.
    Drug and alcohol dependence, 2022, 04-01, Volume: 233

    Topics: Adolescent; Cannabis; gamma-Aminobutyric Acid; Glutamic Acid; Glutamine; Humans; Impulsive Behavior;

2022
Management of Phenibut Use Disorder and Withdrawal in a Geriatric Patient.
    The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry, 2023, Volume: 31, Issue:1

    Topics: Aged; Benzodiazepines; gamma-Aminobutyric Acid; Humans; Hypnotics and Sedatives; Male; Substance-Rel

2023
Physiologically based pharmacokinetic and pharmacodynamic modelling of alprazolam: Implications for anxiety and addiction.
    British journal of clinical pharmacology, 2023, Volume: 89, Issue:8

    Topics: Alprazolam; Anti-Anxiety Agents; Anxiety; gamma-Aminobutyric Acid; Humans; Substance-Related Disorde

2023
Phenibut: A Novel Nootropic With Abuse Potential.
    The primary care companion for CNS disorders, 2020, Aug-13, Volume: 22, Issue:4

    Topics: Adult; gamma-Aminobutyric Acid; Humans; Male; Nootropic Agents; Substance Withdrawal Syndrome; Subst

2020
GABA
    Current topics in behavioral neurosciences, 2022, Volume: 52

    Topics: gamma-Aminobutyric Acid; Humans; Pharmaceutical Preparations; Receptors, GABA-B; Substance-Related D

2022
Sedative-Hypnotic Agents That Impact Gamma-Aminobutyric Acid Receptors: Focus on Flunitrazepam, Gamma-Hydroxybutyric Acid, Phenibut, and Selank.
    Journal of clinical pharmacology, 2021, Volume: 61 Suppl 2

    Topics: Drug Overdose; Flunitrazepam; gamma-Aminobutyric Acid; Humans; Hypnotics and Sedatives; Oligopeptide

2021
Prevalence of Gabapentin Abuse: Comparison with Agents with Known Abuse Potential in a Commercially Insured US Population.
    Clinical drug investigation, 2017, Volume: 37, Issue:8

    Topics: Adolescent; Adult; Amines; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma-Aminobutyric Acid;

2017
Law enforcement-derived data on gabapentin diversion and misuse, 2002-2015: diversion rates and qualitative research findings.
    Pharmacoepidemiology and drug safety, 2017, Volume: 26, Issue:9

    Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Data Collection; Female; Gabapentin; gamma-Aminobut

2017
Dissociative Intoxication and Prolonged Withdrawal Associated With Phenibut: A Case Report.
    Journal of clinical psychopharmacology, 2017, Volume: 37, Issue:4

    Topics: Adult; Baclofen; Delirium; GABA Agonists; gamma-Aminobutyric Acid; Humans; Male; Substance Withdrawa

2017
Prefrontal Glx and GABA concentrations and impulsivity in cigarette smokers and smoking polysubstance users.
    Drug and alcohol dependence, 2017, 10-01, Volume: 179

    Topics: Cigarette Smoking; Cocaine-Related Disorders; gamma-Aminobutyric Acid; Glutamic Acid; Gyrus Cinguli;

2017
You Abused What? Getting High with Unique Medications.
    South Dakota medicine : the journal of the South Dakota State Medical Association, 2017, Volume: 70, Issue:1

    Topics: Amines; Anticonvulsants; Antidiarrheals; Antipsychotic Agents; Antitussive Agents; Cyclohexanecarbox

2017
Policies to mitigate nonmedical use of prescription medications: how should emerging evidence of gabapentin misuse be addressed?
    Expert opinion on drug safety, 2018, Volume: 17, Issue:5

    Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Drug and Narcotic Control; Gabapentin; gamma-Aminob

2018
N-Methyl-d-aspartate receptor co-agonist availability affects behavioral and neurochemical responses to cocaine: insights into comorbid schizophrenia and substance abuse.
    Addiction biology, 2019, Volume: 24, Issue:1

    Topics: Animals; Cocaine; Comorbidity; Dopamine; Dopamine Uptake Inhibitors; gamma-Aminobutyric Acid; Glutam

2019
The FDA and the Next Wave of Drug Abuse - Proactive Pharmacovigilance.
    The New England journal of medicine, 2018, Jul-19, Volume: 379, Issue:3

    Topics: Amines; Analgesics, Opioid; Cyclohexanecarboxylic Acids; Drug Therapy, Combination; Drug Utilization

2018
The Association of Gabapentin Use and Dose With Substance Use Disorders Prior to Inpatient Mental Health Treatment: A Cross-Sectional Study.
    The primary care companion for CNS disorders, 2018, Aug-02, Volume: 20, Issue:4

    Topics: Adult; Amines; Cross-Sectional Studies; Cyclohexanecarboxylic Acids; Dose-Response Relationship, Dru

2018
Cannabinoid dependence induces sustained changes in GABA release in the globus pallidus without affecting dopamine release in the dorsal striatum: A dual microdialysis probe study.
    Addiction biology, 2018, Volume: 23, Issue:6

    Topics: Analysis of Variance; Animals; Basal Ganglia; Benzoxazines; Calcium Channel Blockers; Cannabinoids;

2018
Special Issue on Disease: New Advances in Psychiatry.
    Neuron, 2019, 04-03, Volume: 102, Issue:1

    Topics: Animals; Brain; Cerebellum; Depression, Postpartum; Depressive Disorder; Female; gamma-Aminobutyric

2019
[Pregabalin should be moved to the prescription group B].
    Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke, 2013, Mar-19, Volume: 133, Issue:6

    Topics: Analgesics; Anticonvulsants; Drug and Narcotic Control; gamma-Aminobutyric Acid; Humans; Pregabalin;

2013
Pregabalin abuse among opiate addicted patients.
    European journal of clinical pharmacology, 2013, Volume: 69, Issue:12

    Topics: Adult; Analgesics; Female; gamma-Aminobutyric Acid; Humans; Male; Middle Aged; Opiate Substitution T

2013
Acute dystonic reaction caused by gabapentin.
    The Journal of emergency medicine, 2014, Volume: 46, Issue:3

    Topics: Acute Disease; Adult; Amines; Anti-Anxiety Agents; Cyclohexanecarboxylic Acids; Dystonia; Gabapentin

2014
Factors associated with pregabalin dispensing at higher than the approved maximum dose.
    European journal of clinical pharmacology, 2014, Volume: 70, Issue:2

    Topics: Adolescent; Adult; Aged; Analgesics; Child; Drug Prescriptions; Female; gamma-Aminobutyric Acid; Hum

2014
Gabapentinoid abuse in order to potentiate the effect of methadone: a survey among substance misusers.
    European addiction research, 2014, Volume: 20, Issue:3

    Topics: Amines; Behavior, Addictive; Cyclohexanecarboxylic Acids; Data Collection; Drug Synergism; Gabapenti

2014
Cognitive effects of pregabalin in the treatment of long-term benzodiazepine-use and dependence.
    Human psychopharmacology, 2014, Volume: 29, Issue:3

    Topics: Benzodiazepines; Central Nervous System Agents; Cognition; Cognition Disorders; Female; Follow-Up St

2014
Gabapentin: can it be misused?
    Journal of psychosocial nursing and mental health services, 2014, Volume: 52, Issue:1

    Topics: Amines; Controlled Substances; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma-Aminobutyric A

2014
Phenibut, the appearance of another potentially dangerous product in the United States.
    The American journal of medicine, 2014, Volume: 127, Issue:8

    Topics: Adult; gamma-Aminobutyric Acid; Humans; Hypnotics and Sedatives; Male; Substance-Related Disorders;

2014
Profiles of pregabalin and gabapentin abuse by postmortem toxicology.
    Forensic science international, 2014, Volume: 241

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amines; Anticonvulsants; Chromatography, Liquid; Cyclohe

2014
Ketamine alters cortical integration of GABAergic interneurons and induces long-term sex-dependent impairments in transgenic Gad67-GFP mice.
    Cell death & disease, 2014, Jul-03, Volume: 5

    Topics: Animals; Apoptosis; Calcium; Cell Differentiation; Cerebral Cortex; Female; gamma-Aminobutyric Acid;

2014
Ratio of antibodies to neurotransmitters in the serum of students, occasional drug users.
    Bulletin of experimental biology and medicine, 2014, Volume: 157, Issue:3

    Topics: Adolescent; Adult; Autoantibodies; Dopamine; Female; gamma-Aminobutyric Acid; Glutamic Acid; Humans;

2014
Injection of crushed tablets--a prospective observational study.
    Clinical toxicology (Philadelphia, Pa.), 2014, Volume: 52, Issue:9

    Topics: Adolescent; Adult; Azabicyclo Compounds; Benzodiazepines; Buprenorphine; C-Reactive Protein; Female;

2014
Assessment of subunit-dependent direct gating and allosteric modulatory effects of carisoprodol at GABA(A) receptors.
    Neuropharmacology, 2015, Volume: 97

    Topics: Carisoprodol; Dose-Response Relationship, Drug; GABA Agents; gamma-Aminobutyric Acid; HEK293 Cells;

2015
Abuse and diversion of gabapentin among nonmedical prescription opioid users in Appalachian Kentucky.
    The American journal of psychiatry, 2015, Volume: 172, Issue:5

    Topics: Adult; Amines; Analgesics; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma-Aminobutyric Acid;

2015
Phenibut (4-amino-3-phenyl-butyric acid): Availability, prevalence of use, desired effects and acute toxicity.
    Drug and alcohol review, 2016, Volume: 35, Issue:5

    Topics: Adult; Female; GABA Agonists; gamma-Aminobutyric Acid; Humans; Illicit Drugs; Male; Middle Aged; Pre

2016
GABA and Endocannabinoids Mediate Depotentiation of Schaffer Collateral Synapses Induced by Stimulation of Temperoammonic Inputs.
    PloS one, 2016, Volume: 11, Issue:2

    Topics: Animals; Brain; CA1 Region, Hippocampal; Calcium Channels, L-Type; Cognition Disorders; Endocannabin

2016
Abuse of Gabapentin is Associated with Opioid Addiction.
    The Psychiatric quarterly, 2016, Volume: 87, Issue:4

    Topics: Adult; Amines; Attention Deficit Disorder with Hyperactivity; Comorbidity; Criminals; Cyclohexanecar

2016
A Decade of Gabapentinoid Misuse: An Analysis of the European Medicines Agency's 'Suspected Adverse Drug Reactions' Database.
    CNS drugs, 2016, Volume: 30, Issue:7

    Topics: Adult; Amines; Analgesics, Opioid; Behavior, Addictive; Cyclohexanecarboxylic Acids; Databases, Fact

2016
Challenges of fragmented care in long-term management of pelvic pain.
    The Journal of family practice, 2007, Volume: 56, Issue:3 Suppl Di

    Topics: Acetaminophen; Adult; Amines; Analgesics, Non-Narcotic; Analgesics, Opioid; Anti-Anxiety Agents; Chr

2007
[Gabapentin abuse].
    Medicina clinica, 2010, Feb-06, Volume: 134, Issue:3

    Topics: Adult; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma-Aminobutyric

2010
Gabapentin-induced delirium and dependence.
    Journal of psychiatric practice, 2009, Volume: 15, Issue:4

    Topics: Adult; Amines; Analgesics, Non-Narcotic; Cyclohexanecarboxylic Acids; Delirium; Gabapentin; gamma-Am

2009
Genetic, personality, and environmental predictors of drug use in adolescents.
    Journal of substance abuse treatment, 2010, Volume: 38, Issue:2

    Topics: Adolescent; Adolescent Behavior; Depression; Dopamine; Family; Female; gamma-Aminobutyric Acid; Gene

2010
Pregabalin treatment of anxiety in patients with substance use disorders.
    The Annals of pharmacotherapy, 2010, Volume: 44, Issue:5

    Topics: Anti-Anxiety Agents; Anxiety; gamma-Aminobutyric Acid; Humans; Pregabalin; Substance-Related Disorde

2010
First evidence that drugs of abuse produce behavioral sensitization and cross sensitization in planarians.
    Behavioural pharmacology, 2010, Volume: 21, Issue:4

    Topics: Animals; Behavior, Animal; Caffeine; Central Nervous System Stimulants; Cocaine; Dose-Response Relat

2010
A signal for an abuse liability for pregabalin--results from the Swedish spontaneous adverse drug reaction reporting system.
    European journal of clinical pharmacology, 2010, Volume: 66, Issue:9

    Topics: Adolescent; Adult; Adverse Drug Reaction Reporting Systems; Algorithms; Analgesics; Anticonvulsants;

2010
Pregabalin abuse, dependence, and withdrawal: a case report.
    The American journal of psychiatry, 2010, Volume: 167, Issue:7

    Topics: Alcoholism; Analgesics; Anticonvulsants; gamma-Aminobutyric Acid; Humans; Male; Middle Aged; Pregaba

2010
[Abuse of pregabalin].
    Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke, 2010, Sep-09, Volume: 130, Issue:17

    Topics: Analgesics; Anticonvulsants; gamma-Aminobutyric Acid; Humans; Pregabalin; Substance-Related Disorder

2010
Earlier discovery of pregabalin's dependence potential might have been possible.
    European journal of clinical pharmacology, 2011, Volume: 67, Issue:3

    Topics: Adverse Drug Reaction Reporting Systems; Analgesics; Databases, Factual; gamma-Aminobutyric Acid; Hu

2011
[Yes, pregabalin can be abused!].
    Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke, 2010, Nov-04, Volume: 130, Issue:21

    Topics: Analgesics; Anticonvulsants; gamma-Aminobutyric Acid; Humans; Pregabalin; Substance-Related Disorder

2010
Potential for pregabalin abuse or diversion after past drug-seeking behavior.
    The Journal of the American Osteopathic Association, 2010, Volume: 110, Issue:10

    Topics: Adult; Analgesics; Analgesics, Opioid; Behavior, Addictive; Female; gamma-Aminobutyric Acid; Humans;

2010
Gabapentin blocks methamphetamine-induced sensitization and conditioned place preference via inhibition of α₂/δ-1 subunits of the voltage-gated calcium channels.
    Neuroscience, 2011, Mar-10, Volume: 176

    Topics: Amines; Animals; Blotting, Western; Brain; Calcium Channels; Central Nervous System Stimulants; Cond

2011
Is there a recreational misuse potential for pregabalin? Analysis of anecdotal online reports in comparison with related gabapentin and clonazepam data.
    Psychotherapy and psychosomatics, 2011, Volume: 80, Issue:2

    Topics: Amines; Anticonvulsants; Clonazepam; Cross-Sectional Studies; Cyclohexanecarboxylic Acids; Dose-Resp

2011
[The prescription registry and abuse of pregabalin].
    Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke, 2011, Feb-04, Volume: 131, Issue:3

    Topics: Analgesics; Anticonvulsants; Drug Utilization; gamma-Aminobutyric Acid; Humans; Norway; Pregabalin;

2011
[To misunderstand about pregabalin abuse].
    Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke, 2011, Apr-08, Volume: 131, Issue:7

    Topics: Analgesics; Anticonvulsants; Drug Utilization; gamma-Aminobutyric Acid; Humans; Norway; Pregabalin;

2011
[Clarification about pregabalin and the Norwegian Prescription Database].
    Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke, 2011, May-06, Volume: 131, Issue:8

    Topics: Analgesics; Anticonvulsants; Drug Utilization; gamma-Aminobutyric Acid; Humans; Pregabalin; Registri

2011
Pregabalin in the treatment of refractory bipolar disorders.
    CNS neuroscience & therapeutics, 2012, Volume: 18, Issue:3

    Topics: Bipolar Disorder; gamma-Aminobutyric Acid; Humans; Male; Middle Aged; Pregabalin; Substance-Related

2012
[Lyrical tragedy].
    Ugeskrift for laeger, 2012, Feb-27, Volume: 174, Issue:9

    Topics: Analgesics; Anticonvulsants; gamma-Aminobutyric Acid; Humans; Neuralgia; Pregabalin; Risk Factors; S

2012
Pregabalin in clinical psychiatry and addiction: pros and cons.
    Expert opinion on investigational drugs, 2012, Volume: 21, Issue:9

    Topics: Alcoholism; Anticonvulsants; Anxiety Disorders; Benzodiazepines; Calcium Channels; gamma-Aminobutyri

2012
Gabapentin and pregabalin: abuse and addiction.
    Prescrire international, 2012, Volume: 21, Issue:128

    Topics: Amines; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid; Humans; Pregabalin; Substa

2012
Glutamatergic and GABAergic metabolism in mouse brain under chronic nicotine exposure: implications for addiction.
    PloS one, 2012, Volume: 7, Issue:7

    Topics: Acetates; Animals; Behavior, Animal; Brain; gamma-Aminobutyric Acid; Glucose; Glutamic Acid; Male; M

2012
Pregabalin abuse and dependence in Germany: results from a database query.
    European journal of clinical pharmacology, 2013, Volume: 69, Issue:6

    Topics: Adolescent; Adult; Adverse Drug Reaction Reporting Systems; Aged; Analgesics; Anti-Anxiety Agents; A

2013
[Potentially addictive drugs on reimbursable prescription for chronic severe pain].
    Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke, 2013, Jan-22, Volume: 133, Issue:2

    Topics: Analgesics, Opioid; Chronic Pain; Drug Prescriptions; Drug Utilization; gamma-Aminobutyric Acid; Hum

2013
Phenibut dependence.
    BMJ case reports, 2013, Feb-06, Volume: 2013

    Topics: Adult; Baclofen; GABA-B Receptor Agonists; gamma-Aminobutyric Acid; Humans; Hypnotics and Sedatives;

2013
GABA systems, benzodiazepines, and substance dependence.
    The Journal of clinical psychiatry, 2003, Volume: 64 Suppl 3

    Topics: Alcohol Drinking; Alcohol-Related Disorders; Benzodiazepines; gamma-Aminobutyric Acid; Humans; Hypno

2003
Three cases of zolpidem dependence treated with fluoxetine: the serotonin hypothesis.
    The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry, 2003, Volume: 4, Issue:2

    Topics: Adult; Female; Fluoxetine; GABA Agonists; gamma-Aminobutyric Acid; Humans; Male; Pyridines; Selectiv

2003
Gabapentin for the treatment of ethanol withdrawal.
    Substance abuse, 2003, Volume: 24, Issue:2

    Topics: Acetates; Adult; Alcohol Withdrawal Seizures; Amines; Anticonvulsants; Benzodiazepines; Central Nerv

2003
Hyperalgesic effects of gamma-aminobutyric acid transporter I in mice.
    Journal of neuroscience research, 2003, Aug-15, Volume: 73, Issue:4

    Topics: Analgesics, Opioid; Analysis of Variance; Animals; Brain; Carrier Proteins; Dose-Response Relationsh

2003
The 16th Annual Meeting of the Winter Conference on Neural Plasticity. St. Lucia, West Indies. February 21-28, 2004.
    CNS drug reviews, 2004,Fall, Volume: 10, Issue:3

    Topics: Aging; Animals; Brain; Brain-Derived Neurotrophic Factor; gamma-Aminobutyric Acid; Gene Expression;

2004
Increased GABA release in the central amygdala of ethanol-dependent rats.
    The Journal of neuroscience : the official journal of the Society for Neuroscience, 2004, Nov-10, Volume: 24, Issue:45

    Topics: Alcoholism; Amygdala; Animals; Dose-Response Relationship, Drug; Drug Administration Schedule; Elect

2004
Endocannabinoids regulate interneuron migration and morphogenesis by transactivating the TrkB receptor.
    Proceedings of the National Academy of Sciences of the United States of America, 2005, Dec-27, Volume: 102, Issue:52

    Topics: Animals; Blotting, Western; Brain-Derived Neurotrophic Factor; Cannabinoid Receptor Modulators; Cell

2005
Abuse, dependency and withdrawal with gabapentin: a first case report.
    Pharmacopsychiatry, 2007, Volume: 40, Issue:1

    Topics: Aged; Alcoholism; Amines; Antimanic Agents; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma-A

2007
Opioids block long-term potentiation of inhibitory synapses.
    Nature, 2007, Apr-26, Volume: 446, Issue:7139

    Topics: Analgesics, Opioid; Animals; Calcium; Cyclic GMP; Dopamine; gamma-Aminobutyric Acid; In Vitro Techni

2007
Open-label study of a proprietary treatment program targeting type A gamma-aminobutyric acid receptor dysregulation in methamphetamine dependence.
    Mayo Clinic proceedings, 2007, Volume: 82, Issue:10

    Topics: Adolescent; Adult; Aged; Amines; Cyclohexanecarboxylic Acids; Female; Flumazenil; Gabapentin; gamma-

2007
Altered expression of genes involved in ATP biosynthesis and GABAergic neurotransmission in the ventral prefrontal cortex of suicides with and without major depression.
    Molecular psychiatry, 2009, Volume: 14, Issue:2

    Topics: Adenosine Triphosphate; Adolescent; Adult; Analysis of Variance; Case-Control Studies; Depressive Di

2009
Pregabalin in the discontinuation of long-term benzodiazepines' use.
    Human psychopharmacology, 2008, Volume: 23, Issue:4

    Topics: Adult; Aged; Anti-Anxiety Agents; Anticonvulsants; Anxiety Disorders; Benzodiazepines; Cognition; Fe

2008
gamma-Aminobutyric acid-ergic analgesia: implications for gamma-aminobutyric acid-ergic therapy for drug addictions.
    Drug and alcohol dependence, 1984, Volume: 14, Issue:2

    Topics: Animals; Baclofen; Brain; Drug Tolerance; Endorphins; GABA Antagonists; gamma-Aminobutyric Acid; Hum

1984
[Benzodiazepine physical dependence. 6 cases (author's transl)].
    La Nouvelle presse medicale, 1980, Jun-28, Volume: 9, Issue:28

    Topics: Adult; Aged; Anti-Anxiety Agents; Benzodiazepines; Dreams; Electroencephalography; Female; gamma-Ami

1980
Long term use and abuse of benzodiazepines.
    Pharmakopsychiatrie, Neuro-Psychopharmakologie, 1980, Volume: 13, Issue:5

    Topics: Adult; Anti-Anxiety Agents; Anxiety; Benzodiazepines; Female; gamma-Aminobutyric Acid; Humans; Male;

1980
Antagonists of benzodiazepines: functional aspects.
    Advances in biochemical psychopharmacology, 1983, Volume: 38

    Topics: Animals; Anti-Anxiety Agents; Benzodiazepinones; Carbolines; Chlorides; Flumazenil; GABA Antagonists

1983
Neuropharmacology of buspirone.
    Psychopathology, 1984, Volume: 17 Suppl 3

    Topics: Animals; Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Biomechanical Phenomena; Buspirone;

1984
[Suppression of the opiate withdrawal syndrome with GABA analogs, low-dose psychotropic drugs and acupuncture].
    Minerva medica, 1982, Mar-31, Volume: 73, Issue:13

    Topics: Acupuncture Therapy; Adult; Dose-Response Relationship, Drug; gamma-Aminobutyric Acid; Humans; Male;

1982
Glucocorticoid receptor activation potentiates the morphine-induced adaptive increase in dopamine D-1 receptor efficacy in gamma-aminobutyric acid neurons of rat striatum/nucleus accumbens.
    The Journal of pharmacology and experimental therapeutics, 1995, Volume: 274, Issue:3

    Topics: Adenylyl Cyclases; Animals; Cells, Cultured; Corpus Striatum; Dexamethasone; Enzyme Activation; gamm

1995
[Changes in GABAA/benzodiazepine receptor complex function in the pentobarbital-dependent rat].
    Nihon shinkei seishin yakurigaku zasshi = Japanese journal of psychopharmacology, 1995, Volume: 15, Issue:3

    Topics: Animals; Binding Sites; Brain; Down-Regulation; Drug Tolerance; gamma-Aminobutyric Acid; In Vitro Te

1995
[Changes in GABAA/benzodiazepine receptor complex function in the pentobarbital-dependent rat. II: Strain differences between Lewis and Wistar-Kyoto rats].
    Nihon shinkei seishin yakurigaku zasshi = Japanese journal of psychopharmacology, 1995, Volume: 15, Issue:4

    Topics: Animals; Bicuculline; Brain; Chlorine; Ethanol; Female; Flunitrazepam; GABA Antagonists; GABA Modula

1995
Diazepam physical dependence and withdrawal in rats is associated with alteration in GABAA receptor function.
    Life sciences, 1996, Volume: 59, Issue:19

    Topics: Animals; Benzodiazepines; Cerebral Cortex; Chloride Channels; Chlorides; Diazepam; Flumazenil; Fluni

1996
Glycyldodecylamide, a phencyclidine behavioral antagonist, blocks cortical glycine uptake: implications for schizophrenia and substance abuse.
    Psychopharmacology, 1997, Volume: 129, Issue:1

    Topics: Animals; Cerebral Cortex; Dizocilpine Maleate; Excitatory Amino Acid Antagonists; gamma-Aminobutyric

1997
A naturalistic study of the use of vigabatrin, lamotrigine and gabapentin in adults with learning disabilities.
    Seizure, 1997, Volume: 6, Issue:2

    Topics: Acetates; Adult; Aged; Amines; Anticonvulsants; Comorbidity; Cyclohexanecarboxylic Acids; Dose-Respo

1997
Gabapentin abuse in a cocaine user: implications for treatment?
    Journal of clinical psychopharmacology, 1997, Volume: 17, Issue:5

    Topics: Acetates; Adult; Amines; Anticonvulsants; Crack Cocaine; Cyclohexanecarboxylic Acids; Female; Gabape

1997
Drug dependence study on vigabatrin in rhesus monkeys and rats.
    Arzneimittel-Forschung, 1997, Volume: 47, Issue:10

    Topics: Analgesics, Opioid; Animals; Anticonvulsants; Barbital; Conditioning, Operant; Female; gamma-Aminobu

1997
Gamma-hydroxybutyric acid: an endogenous neuromodulator with abuse potential?
    Trends in pharmacological sciences, 1999, Volume: 20, Issue:4

    Topics: Animals; Dopamine; gamma-Aminobutyric Acid; Humans; Hydroxybutyrates; Opioid Peptides; Substance-Rel

1999
5-HT receptor knockout mice: pharmacological tools or models of psychiatric disorders.
    Annals of the New York Academy of Sciences, 1999, Apr-30, Volume: 868

    Topics: 3,4-Dihydroxyphenylacetic Acid; Aggression; Animals; Behavior, Animal; Cocaine; Disease Models, Anim

1999
GABA GABA A: modulating sensitivity to drugs and alcohol.
    Molecular psychiatry, 2000, Volume: 5, Issue:1

    Topics: Brain Chemistry; gamma-Aminobutyric Acid; Humans; Receptors, GABA-A; Substance-Related Disorders

2000
Gabapentin use in benzodiazepine dependence and detoxification.
    Canadian journal of psychiatry. Revue canadienne de psychiatrie, 2001, Volume: 46, Issue:3

    Topics: Acetates; Alprazolam; Amines; Anti-Anxiety Agents; Cyclohexanecarboxylic Acids; Excitatory Amino Aci

2001
Psychic dependence? A different formulation of the problem with a view to the reorientation of therapy for chronic drug addiction.
    Acta psychiatrica Scandinavica, 1977, Volume: 56, Issue:5

    Topics: Aminobutyrates; Antidepressive Agents, Tricyclic; Depression; gamma-Aminobutyric Acid; Glutamine; Hu

1977
Changes in brain levels of cyclic nucleotides and gamma-aminobutyric acid in barbiturate dependence and withdrawal.
    European journal of pharmacology, 1979, Apr-15, Volume: 55, Issue:2

    Topics: Acoustic Stimulation; Animals; Barbital; Barbiturates; Brain; Cyclic AMP; Cyclic GMP; gamma-Aminobut

1979
[Psychological dependence? A possible different formulation of the problem for a therapeutic rearrangement in chronic drug addictions].
    Minerva medica, 1977, Jul-07, Volume: 68, Issue:33

    Topics: Antidepressive Agents; gamma-Aminobutyric Acid; Glutamine; Humans; Piracetam; Substance-Related Diso

1977
Physiologo-biochemical bases of drug dependence treatment by electro-acupuncture.
    Addictive behaviors, 1979, Volume: 4, Issue:2

    Topics: Acetylcholine; Acupuncture Therapy; Catecholamines; Electric Stimulation; gamma-Aminobutyric Acid; H

1979
[Gynecomastia during benzodiazepine abuse].
    Ugeskrift for laeger, 1979, Sep-24, Volume: 141, Issue:39

    Topics: Diazepam; gamma-Aminobutyric Acid; Gynecomastia; Humans; Male; Middle Aged; Pituitary Gland, Anterio

1979
Changes of taurine content in the brain tissue of barbiturate-dependent rats.
    Biochemical pharmacology, 1978, Volume: 27, Issue:15

    Topics: Animals; Aspartic Acid; Barbiturates; Brain Chemistry; gamma-Aminobutyric Acid; Glutamates; Humans;

1978
Effects of the irreversible inhibition of GABA transaminase upon some morphine effects.
    Neuropharmacology, 1979, Volume: 18, Issue:3

    Topics: 4-Aminobutyrate Transaminase; Analgesia; Animals; Drug Tolerance; Female; gamma-Aminobutyric Acid; H

1979
Pharmacological manipulation of gamma-aminobutyric acid (GABA) in morphine analgesia, tolerance and physical dependence.
    Life sciences, 1976, May-15, Volume: 18, Issue:10

    Topics: Alanine; Aminobutyrates; Aminooxyacetic Acid; Analgesia; Animals; Bicuculline; Biological Transport;

1976
Development of tolerance to the anticonvulsant effect of vigabatrin in amygdala-kindled rats.
    European journal of pharmacology, 1992, Mar-31, Volume: 213, Issue:3

    Topics: Amino Acids; Aminocaproates; Amygdala; Animals; Anticonvulsants; Disease Models, Animal; Drug Admini

1992
The effect of ethanol on 35S-TBPS binding to mouse brain membranes in the presence of chloride.
    Pharmacology & toxicology, 1989, Volume: 65, Issue:5

    Topics: 4-Acetamido-4'-isothiocyanatostilbene-2,2'-disulfonic Acid; 4,4'-Diisothiocyanostilbene-2,2'-Disulfo

1989
From the Alcohol, Drug Abuse, and Mental Health Administration.
    JAMA, 1989, May-12, Volume: 261, Issue:18

    Topics: Diabetes Mellitus, Type 2; Ethanol; Female; Fetal Growth Retardation; gamma-Aminobutyric Acid; Human

1989
Evidence for GABA tolerance in barbiturate-dependent and withdrawn mice.
    Neuropharmacology, 1985, Volume: 24, Issue:5

    Topics: Animals; Barbital; Barbiturates; Drug Tolerance; Female; gamma-Aminobutyric Acid; Humans; Imidazoles

1985
[Short- and long-acting benzodiazepines].
    Nederlands tijdschrift voor geneeskunde, 1988, Oct-15, Volume: 132, Issue:42

    Topics: Absorption; Benzodiazepines; Drug Tolerance; gamma-Aminobutyric Acid; Humans; Substance-Related Diso

1988